Back to User profile » Dr Shuqun Li
Papers published by Dr Shuqun Li:
Prognostic Value of the SEA Score in Double-Negative DCP/AFP Unresectable HCC with Triple Therapy
Lin H, Ran F, Wu J, Huang C, Wu J, Liu C, Wang X, Ya H, Jiang K, Gu J, Yan M, Li S
Journal of Hepatocellular Carcinoma 2026, 13:606282
Published Date: 16 June 2026
Efficacy and Safety Analysis of Transarterial Chemoembolization Combined with Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma
Qin H, Jiang K, Liu C, Lin H, Xia J, Ya H, Gu J, Suo L, Li B, Deng X, Wang D, Huang X, Li S
Journal of Hepatocellular Carcinoma 2025, 12:1943-1955
Published Date: 27 August 2025
Whether Adjuvant TACE Plus TKI Therapy is More Effective Than TACE Alone in HCC Patients at High Risks of Recurrence Following Radical Hepatectomy
Li Y, Wang K, Qin H, Huo S, Jiang K, Xia J, Gu J, Ya H, Suo L, Wang D, Huang X, Li S
Journal of Hepatocellular Carcinoma 2025, 12:1767-1780
Published Date: 11 August 2025
Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
Jin M, Jiang ZQ, Qin JH, Qin HX, Jiang KW, Ya HX, Gu J, Gui MR, Li YH, Xu LK, Fu HX, Xiao XH, Li SQ
Journal of Hepatocellular Carcinoma 2024, 11:2309-2320
Published Date: 25 November 2024
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?
Wu JY, Wu JY, Liu DY, Li H, Zhuang SW, Li B, Zhou JY, Huang JY, Zhang ZB, Li SQ, Yan ML, Wang YD
Journal of Hepatocellular Carcinoma 2023, 10:2161-2171
Published Date: 5 December 2023
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Li SQ, Wu JY, Wu JY, Xie H, Li JH, Zeng ZX, Fu YK, Liu DY, Li H, Chen WZ, Huang JY, Yan ML
Journal of Hepatocellular Carcinoma 2023, 10:1799-1811
Published Date: 11 October 2023